Experienced in Microscopic Polyangiitis

Liqi Q. Bi

China Japan Union Hospital Of Jilin University
Changchun, CN 
Experienced in Microscopic Polyangiitis
China Japan Union Hospital Of Jilin University
Changchun, CN 
OverviewLocationsClinical Research

Overview

Liqi Bi practices in Changchun, China. Bi is rated as an Experienced expert by MediFind in the treatment of Microscopic Polyangiitis. Their top areas of expertise are Arthritis, Rheumatoid Arthritis (RA), Ankylosing Spondylitis, and Systemic Lupus Erythematosus (SLE).

Their clinical research consists of co-authoring 47 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Microscopic Polyangiitis.

Locations

China Japan Union Hospital of Jilin University
Changchun, 130033, China
Other Locations
China Japan Union Hospital Of Jilin University, No. 126 Xiantai Street, Changchun, 130000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drug: Ixekizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
Enrollment Status: Terminated
Publish Date: June 21, 2022
Intervention Type: Drug, Other
Study Drug: Hemay005
Study Phase: Phase 2
View 3 Less Clinical Trials

47 Total Publications

Iguratimod inhibits protein citrullination and inflammation by downregulating NBCe2 in patients with rheumatoid arthritis.
Iguratimod inhibits protein citrullination and inflammation by downregulating NBCe2 in patients with rheumatoid arthritis.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: December 13, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Bi's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile